Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine

Br J Clin Pharmacol. 1997 Dec;44(6):549-55. doi: 10.1046/j.1365-2125.1997.t01-1-00626.x.

Abstract

Aims: Using human liver microsomes from donors of the CYP2D6 poor and extensive metabolizer genotypes, the role of individual cytochromes P-450 in the oxidative metabolism of dihydrocodeine was investigated.

Methods: The kinetics of formation of N- and O-demethylated metabolites, nordihydrocodeine and dihydromorphine, were determined using microsomes from six extensive and one poor metabolizer and the effects of chemical inhibitors selective for individual P-450 enzymes of the 1A, 2A, 2C, 2D, 2E and 3A families and of LKM1 (anti-CYP2D6) antibodies were studied.

Results: Nordihydrocodeine was the major metabolite in both poor and extensive metabolizers. Kinetic constants for N-demethylation derived from the single enzyme Michaelis-Menten model did not differ between the two groups. Troleandomycin and erythromycin selectively inhibited N-demethylation in both extensive and poor metabolizers. The CYP3A inducer, alpha-naphthoflavone, increased N-demethylation rates. The kinetics of formation of dihydromorphine in both groups were best described by a single enzyme Michaelis-Menten model although inhibition studies in extensive metabolizers suggested involvement of two enzymes with similar Km values. The kinetic constants for O-demethylation were significantly different in extensive and poor metabolizers. The extensive metabolizers had a mean intrinsic clearance to dihydromorphine more than ten times greater than the poor metabolizer. The CYP2D6 chemical inhibitors, quinidine and quinine, and LKM1 antibodies inhibited O-demethylation in extensive metabolizers; no effect was observed in microsomes from a poor metabolizer.

Conclusions: CYP2D6 is the major enzyme mediating O-demethylation of dihydrocodeine to dihydromorphine. In contrast, nordihydrocodeine formation is predominantly catalysed by CYP3A.

MeSH terms

  • Analgesics, Opioid / pharmacokinetics*
  • Antibodies, Blocking / pharmacology
  • Aryl Hydrocarbon Hydroxylases*
  • Biotransformation
  • Codeine / analogs & derivatives*
  • Codeine / pharmacokinetics
  • Cytochrome P-450 CYP2D6 / biosynthesis
  • Cytochrome P-450 CYP2D6 / metabolism
  • Cytochrome P-450 CYP2D6 Inhibitors
  • Cytochrome P-450 CYP3A
  • Cytochrome P-450 Enzyme Inhibitors
  • Cytochrome P-450 Enzyme System / biosynthesis
  • Cytochrome P-450 Enzyme System / metabolism*
  • Dealkylation
  • Enzyme Induction / drug effects
  • Enzyme Induction / physiology
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Kinetics
  • Microsomes, Liver / enzymology
  • Oxidoreductases, N-Demethylating / antagonists & inhibitors
  • Oxidoreductases, N-Demethylating / biosynthesis
  • Oxidoreductases, N-Demethylating / metabolism

Substances

  • Analgesics, Opioid
  • Antibodies, Blocking
  • Cytochrome P-450 CYP2D6 Inhibitors
  • Cytochrome P-450 Enzyme Inhibitors
  • Enzyme Inhibitors
  • Cytochrome P-450 Enzyme System
  • Aryl Hydrocarbon Hydroxylases
  • Cytochrome P-450 CYP2D6
  • Cytochrome P-450 CYP3A
  • Oxidoreductases, N-Demethylating
  • dihydrocodeine
  • Codeine